Carl Zeiss Meditec sees FY 2025/26 revenue at EUR 2.15 billion-2.2 billion

Reuters2026/08/06 05:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Carl Zeiss Meditec guided fiscal 2025/26 revenue to about € 2.15 billion-€ 2.2 billion amid a volatile macro backdrop.
Adjusted EBITA margin forecast at 8%-10%, excluding non-recurring effects seen at a mid-double-digit million-euro amount.
FY 2024/25 EBITA was € 257.7 million, implying an 11.6% margin.
Ophthalmology SBU expected to book about € 150 million goodwill impairment in Q4 2025/26.
Medium-term outlook targets at least mid-single-digit organic growth, adjusted EBITA margin recovery to about 15%, long-run sustainable margin 16%-20%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carl Zeiss Meditec AG published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Carl Zeiss Meditec sees FY 2025/26 revenue at EUR 2.15 billion-2.2 billion

You may also like

Crypto prices